Internal Medicine, Family Medicine, Cardiology

Atrial Fibrillation and the New Anticoagulants, Now What?

Robert D. McBane, M.D.

Anticoagulation Therapy, the new anticoagulation agents available and a framework to use these drugs in a way that makes sense.

Share via Email

Jump to...

  • 0:00

    Introduction and Goals

  • 4:59

    Not Just Warfarin Any Longer - Safer, Better Options

  • 5:15

    Four Direct Factor Inhibitors

  • 6:00

    Advantages to Oral Direct Factor Inhibitors

  • 7:41

    3 Indications for these Novel Anticoagulants

  • 8:06

    Case 1: 84 y/o Paroxysmal Atrial Fib for 2 Years

  • 9:10

    Atrial Fibrillation Drug Trials Results You Need to Know About

  • 11:53

    2014 ACC/AHA Guidelines and NVAF

  • 12:22

    Bottom Line: Stable Dose of Warfarin, No Complications, Continue Warfarin

  • 12:59

    Case 2: 77 y/o Female Permanent Atrial Fib

  • 14:25

    Aristotle Trial: Apixaban vs Warfarin

  • 16:06

    Averroes Trial: Apixaban vs. Aspirin

  • 17:56

    GI Bleeding Rates - Compare to Warfarin

  • 18:43

    Drug-Induced Esophagitis Dabigatran

  • 19:41

    Bottom Line: Apixaban Afety Advantage for Patients at Risk of Major Bleeding

  • 20:37

    Acute Treatment Trials: VTE - What They Tell Us about Correct Usage

  • 21:46

    Case 3: 38 y/o Male Mid-Femoral DVT

  • 24:42

    Case 3: Part 2 - Which Agent Most Effective?

  • 26:05

    Case 3: Part 3 - Which Agent is the Safest?

  • 27:07

    Summary: Compared LMWH/Warfarin for VTE

  • 27:37

    Bottom Line: VTE

  • 27:56

    Case 3: Part 4 - Long Term Recommendations?

  • 28:55

    Treatment for three months, then Secondary Prevention

  • 29:09

    Balance of VTE Recurrence Against the Risk of Major Bleeding

  • 30:12

    Who gets Secondary Treatment?

  • 30:18

    Risk Factors Not Sufficient to Influence Treatment Duration

  • 30:46

    Bottom Line: Secondary Prevention

  • 30:49

    4 Important Trials: Assessing Extended Therapy for VTE

  • 34:18

    If the Patient Bleeds: Antidotes - Direct Factor Inhibitors